All In Biotech

Drug Trial Radar · NCT07473167

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

A Multi-center, Single Arm, Open-label Phase 1/2 Clinical Trial to Evaluate Safety, and to Explore Efficacy of TC011(CD19 Targeted CAR-T) in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

98

Planned (sponsor's estimate)

Start

Aug 3, 2023

Primary completion

Feb 11, 2028

Study completion Mar 10, 2028

Sponsor

Lead sponsor
TICAROS Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.

Conditions

  • Relapsed Large B-cell Lymphoma
  • Refractory Large B-cell Lymphoma
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • High-grade B-cell Lymphoma (HGBL)
  • Transformed Follicular Lymphoma (TFL)
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Interventions

  • TC011Drug

    Anti-CD19 Chimeric Antigen Receptor T cell

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase1: Occurrence of Dose-Limiting Toxicities (DLTs)Time frame: Up to 4 weeks after TC011 infusion
  2. Phase1: Determination of Maximum Tolerated Dose (MTD)Time frame: up to 4weeks after TC011 infusion
  3. Phase1: Determination of Recommended Phase 2 Dose (RP2D)Time frame: Up to 12 weeks after TC011 infusion
  4. Phase 1: The number and incidence rate of treatment-emergent adverse events (TEAEs) as well as serious adverse events (SAEs) will be assessedTime frame: Up to 12 weeks after TC011 infusion
  5. Phase1: Number of participants with abnormal physical examination findingsTime frame: Baseline through Week 12
  6. Phase1: Number of participants with abnormal vital signsTime frame: Baseline through Week 12
  7. Phase1: Number of participants with abnormal ECG readingsTime frame: Baseline through Week 12
  8. Phase 1 : Number of participants with abnormal laboratory test resultsTime frame: Baseline through Week 12
  9. Phase 1 : Presence of Replication-Competent Lentivirus (RCL) Through Week 12Time frame: Baseline through Week 12
  10. Phase 2 : Objective Response Rate (ORR)Time frame: up to 24 weeks after TC011 infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.